Latest news with #GlobusMedical
Yahoo
27-05-2025
- Business
- Yahoo
BTIG Downgrades Globus Medical (GMED) to Neutral on Spine Business Concerns
On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following the downgrade. Globus Medical is a medical device company specializing in healthcare solutions primarily for musculoskeletal disorders. In early May, the company reported weaker-than-expected Q1 2025 results, and the analyst believes this could signal further challenges across its business lines, particularly in the Spine division, which has now completed one year since the acquisition of NuVasive Inc. A doctor in a medical facility demonstrating a procedure with a state-of-the-art medical device. The downgrade also reflects negative cross-reads from industry peer Medtronic plc (NYSE:MDT), whose Q4 results beat expectations for both organic revenue growth and its 2026 outlook. The analyst suggests that this outperformance may indicate that Medtronic is gaining market share at the expense of competitors, such as Globus. As a result, the analyst expects Globus Medical to factor in these headwinds and update its FY 2025 guidance. Until the company addresses these challenges, the analyst anticipates the stock will underperform relative to previous expectations. While we acknowledge the potential of GMED as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GMED and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Insider
20-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS – Research Report), Globus Medical (GMED – Research Report) and Ramsay Health Care (RMSYF – Research Report). Confident Investing Starts Here: Pyxis Oncology (PYXS) In a report issued on May 15, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $8.00. The company's shares closed last Monday at $1.23, close to its 52-week low of $0.99. According to Timashev is a 1-star analyst with an average return of -0.5% and a 32.8% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Design Therapeutics. Currently, the analyst consensus on Pyxis Oncology is a Strong Buy with an average price target of $6.83, representing a 483.8% upside. In a report issued on May 16, Leerink Partners also maintained a Buy rating on the stock with a $7.00 price target. Globus Medical (GMED) RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical on May 15 and set a price target of $95.00. The company's shares closed last Monday at $61.05. According to Chadha is a 2-star analyst with an average return of 0.5% and a 48.6% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Tandem Diabetes Care. Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $87.38, implying a 44.6% upside from current levels. In a report issued on May 8, Morgan Stanley also maintained a Buy rating on the stock with a $100.00 price target. Ramsay Health Care (RMSYF) RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Ramsay Health Care on May 15 and set a price target of A$41.00. The company's shares closed last Thursday at $22.00. According to Wong-Pan is ranked #7861 out of 9558 analysts. Ramsay Health Care has an analyst consensus of Hold, with a price target consensus of $25.32, implying an 11.2% upside from current levels. In a report issued on May 5, Morgan Stanley also maintained a Hold rating on the stock with a A$37.20 price target.
Yahoo
15-05-2025
- Business
- Yahoo
Globus Medical Announces $500 Million Share Repurchase Program
AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company's outstanding common stock. 'We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation,' said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. 'Given our strong track record of growth and profitability, we are confident in the long-term strength of our business. This repurchase authorization reflects that confidence and reinforces our commitment to delivering long-term value to our shareholders.' The timing and actual number of shares repurchased will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities. The repurchase program will be executed consistent with the company's capital allocation strategy of prioritizing investment to grow the business over the long term. Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. The Company intends to utilize its cash reserves to fund the share repurchase program. About Globus Medical, Inc. Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as 'believe,' 'may,' 'might,' 'could,' 'will,' 'aim,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'plan' and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of the NuVasive and Nevro businesses and our ability to successfully integrate and achieve anticipated synergies with the integration, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosure of Globus Medical contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled 'Risk Factors' and 'Cautionary Note Concerning Forward-Looking Statements,' and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. Investor contact:Brian KearnsSenior Vice President, Corporate Development and Investor Relations(610) 930-1800investors@ Media contact:Moran Chavezmedia@
Yahoo
08-05-2025
- Business
- Yahoo
Globus Medical (NYSE:GMED) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops 17.1%
Medical device company Globus Medical (NYSE:GMED) missed Wall Street's revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company's full-year revenue guidance of $2.85 billion at the midpoint came in 4.2% above analysts' estimates. Its non-GAAP profit of $0.68 per share was 8.6% below analysts' consensus estimates. Is now the time to buy Globus Medical? Find out in our full research report. Revenue: $598.1 million vs analyst estimates of $627.6 million (1.4% year-on-year decline, 4.7% miss) Adjusted EPS: $0.68 vs analyst expectations of $0.74 (8.6% miss) Adjusted EBITDA: $177.8 million vs analyst estimates of $195.4 million (29.7% margin, 9% miss) The company lifted its revenue guidance for the full year to $2.85 billion at the midpoint from $2.68 billion, a 6.5% increase Management lowered its full-year Adjusted EPS guidance to $3.15 at the midpoint, a 8.7% decrease Operating Margin: 16.2%, up from 1.3% in the same quarter last year Free Cash Flow Margin: 23.6%, up from 3.9% in the same quarter last year Constant Currency Revenue was flat year on year (120% in the same quarter last year) Market Capitalization: $9.68 billion With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures. A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Globus Medical's sales grew at an exceptional 25.9% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Globus Medical's annualized revenue growth of 53.3% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated. We can dig further into the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 61.4% year-on-year growth. Because this number is better than its normal revenue growth, we can see that foreign exchange rates have been a headwind for Globus Medical. This quarter, Globus Medical missed Wall Street's estimates and reported a rather uninspiring 1.4% year-on-year revenue decline, generating $598.1 million of revenue. Looking ahead, sell-side analysts expect revenue to grow 11.7% over the next 12 months, a deceleration versus the last two years. Still, this projection is noteworthy and implies the market sees success for its products and services. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Globus Medical has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 12.1%, higher than the broader healthcare sector. Looking at the trend in its profitability, Globus Medical's operating margin decreased by 6.5 percentage points over the last five years. This performance was caused by more recent speed bumps as the company's margin fell by 12.1 percentage points on a two-year basis. We're disappointed in these results because it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Globus Medical generated an operating profit margin of 16.2%, up 14.9 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Globus Medical's EPS grew at a spectacular 13.8% compounded annual growth rate over the last five years. However, this performance was lower than its 25.9% annualized revenue growth, telling us the company became less profitable on a per-share basis as it expanded. We can take a deeper look into Globus Medical's earnings quality to better understand the drivers of its performance. As we mentioned earlier, Globus Medical's operating margin improved this quarter but declined by 6.5 percentage points over the last five years. Its share count also grew by 36.8%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders. In Q1, Globus Medical reported EPS at $0.68, up from $0.63 in the same quarter last year. Despite growing year on year, this print missed analysts' estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects Globus Medical's full-year EPS of $3.10 to grow 14%. We were impressed by Globus Medical's optimistic full-year revenue guidance, which blew past analysts' expectations. On the other hand, its full-year EPS guidance missed along with its revenue, EPS, and EBITDA. Overall, this was a softer quarter. The stock traded down 17.1% to $60 immediately following the results. Globus Medical's latest earnings report disappointed. One quarter doesn't define a company's quality, so let's explore whether the stock is a buy at the current price. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Earnings To Watch: Globus Medical (GMED) Reports Q1 Results Tomorrow
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after market close. Here's what to look for. Globus Medical beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $657.3 million, up 6.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and a narrow beat of analysts' constant currency revenue estimates. Is Globus Medical a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Globus Medical's revenue to grow 3.4% year on year to $627.6 million, slowing from the 119% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.74 per share. Globus Medical Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Globus Medical has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.5% on average. Looking at Globus Medical's peers in the medical devices & supplies - specialty segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 22.7%, beating analysts' expectations by 3.1%, and Integer Holdings reported revenues up 7.3%, topping estimates by 2%. Inspire Medical Systems traded up 1.8% following the results while Integer Holdings was also up 2.6%. Read our full analysis of Inspire Medical Systems's results here and Integer Holdings's results here. There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 5.9% on average over the last month. Globus Medical is up 2.6% during the same time and is heading into earnings with an average analyst price target of $97.46 (compared to the current share price of $70.43). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
